1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Consensus Outlook: Multiple Sclerosis

Consensus Outlook: Multiple Sclerosis

  • September 2013
  • -
  • Firstword Pharma
  • -
  • 35 pages

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
Timely event-driven market forecast report and data analysis updates over the next 12 months

Key Benefits

Multiple Sclerosis: On the cusp of a treatment revolution will allow you to

Evaluate future sales forecasts and predicted market growth
Map your market parameters and chart commercial prospects
Assess market share by company and product
Tailor your strategic and investment focus based on the competition
Set proactive launch and branding strategies
Keep up with event-driven market data updates

Reasons to Buy this Report

Forecast analysis report and data model

The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Historical MS sales from 2007–2012
Forecast MS sales from 2013-2017
Key competitors and drug developers
Predicted product positioning
Current and late-stage pipeline drugs
Future event mapping to forecast data points
Comparative clinical trial results

FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters:

Market size
Product sales
Company forecasts
Company, brand, and drug class
Mechanism of action Future events

Event Assessments

Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.


For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.

Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.

Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.

Table Of Contents

Consensus Outlook: Multiple Sclerosis
Consensus Outlook
1.Forecast Data Model (Excel)
1.1.Tabs: Market size
1.2.Product sales
1.3.Company forecast
1.4.Mechanism of action
1.5.Future Events

2.Forecast Analysis Report (PDF)
2.1. Contents: FirstWord Analysis Highlights
2.2.Research Methodology
2.3.Multiple Sclerosis Marketplace
2.4.Key Multiple Sclerosis Developers
2.5.Multiple Sclerosis Class Dynamics
2.6.Tecfidera (dimethyl fumarate; Biogen) forecast
2.7.Aubagio (teriflunomide; Sanofi) forecast
2.8.Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
2.9.Tysabri (natalizumab; Biogen) forecast
2.10.Copaxone (glatiramer acetate; Teva) forecast
2.11.Avonex (interferon beta-1a; Biogen) forecast
2.12.Betaseron (interferon beta-1b; Bayer) forecast
2.13.Rebif (interferon beta-1a; Merck Serono) forecast
2.14.Extavia (interferon beta-1b; Novartis) forecast
2.15.Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
2.16.Laquinimod (Teva/Active Biotech) forecast
2.17.Daclizumab HYP (Biogen/AbbVie) forecast
2.18.Ocrelizumab (Biogen/Roche/Biogen) forecast

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 718 303 2384

Purchase Reports From Reputable Market Research Publishers

Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • July 2015
  • by Firstword Pharma

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting ...

Idiopathic Pulmonary Fibrosis: KOL Insight

Idiopathic Pulmonary Fibrosis: KOL Insight

  • $ 7 495
  • Industry report
  • May 2015
  • by Firstword Pharma

Roche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as ...

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • May 2015
  • by GBI Research

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation Summary Highly Innovative and Diverse Pipeline The Duchenne Muscula ...

Download Unlimited Documents from Trusted Public Sources

Therapy Supply

  • August 2015
    2 pages
  • Therapy  

    Nursing Home  

View report >

Global Therapeutics Supply - Forecast

  • August 2015
    2 pages
  • Therapeutics  


  • World  

View report >

Nursing Home Industry in the UK and the US

  • August 2015
    14 pages
  • Nursing Home  

  • United Kingdom  

    United States  


View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.